Select Region:
Select Language:

Today we are interviewing Jose García, Project Manager of Quibim’s clinical trials, as well as Ángel Alberich-Bayarri, CEO and founder of Quibim.

We have discussed the benefits of quantitative imaging analysis in previous episodes, but in this interview we are analyzing the cost effectiveness of this solution.  Ángel explained that if we take a long term holistic approach, we would be able to have a real time monitoring of the statistical analysis of the study.  This alone saves Sponsors potentially millions of dollars, but even beyond that, patient selection for future or current clinical trials can be more efficiently targeted when utilizing imaging biomarkers.

Jose also explained that the utilization of Quibim’s technology is a natural advancement in the evolution of how we conduct and analyze clinical research studies.  Although we are at the forefront of this revolution, costs are going to continue to drop as the required technology for real time quantitative analysis advances.  Jose used the analogy of dispersed light versus the precision of a laser beam and how Quibim’s capabilities more accurately reflect the latter.

In regards to the macro-analysis of cost saving measures, centralizing the process of qualitative and quantitative image reading services as it becomes increasingly quantitative due to the parameters being extracted.  Artificial intelligence and algorithms will also play a large role in the quantitative analysis and will assist the qualitative readings of humans, such as radiologists.  The more we can automate the quantitative process, the greater the cost savings are made available to the study sponsors.

Towards the end of the interview, we discussed in silico studies, where, by utilizing a “digital twin” of an actual study subject, sponsors could in theory create a simulated clinical trial and determine outcomes while reducing potential risk to human participants, specifically in phase 1 trials primarily.  Quibim is at the forefront of this movement, and we will focus on this topic in our next episode!

Katherine Wilisch Ramírez